Compare Davita Inc (DVA) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Davita Inc trades at $230.44 (market cap $14.92B), while GraniteShares 2x Long NVDA Daily ETF trades at $32.97. The key difference: Davita Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| DVA | NVDL | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $235.71 | $43.02 |
52-Week Low | $103.87 | $21.76 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $30.7, down 7.05% in the last 24 hours, reflecting high volatility tied to its leveraged exposure to NVIDIA. Technical indicators show a bullish trend with moving averages supporting upward momentum, while oscillators remain neutral. Recent stock splits on June 25 and 26, 2026, adjusted the share structure, but key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity. The ETF's performance is directly driven by daily NVIDIA price movements, amplified by its 2x leverage.
The outlook for NVDL hinges on NVIDIA's AI-driven growth, offering potential for high returns but with significant risk due to leverage compounding losses during downturns. Investors face volatility risks, as seen in a 12% single-day drop on June 5, 2026, and must monitor NVIDIA's earnings and broader semiconductor trends. Caution is advised given the lack of traditional fundamentals and the ETF's reset mechanism, which can erode value over time in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
